Array Biopharma (ARRY) Says Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median OS in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial

February 6, 2018 8:03 AM

Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced results of the planned ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found